IFNG and HIV infectious disease: However, the half-life of interferon is very short in vivo, making it difficult to model the sustained levels observed during human HIV infection or IFN-γ treatment in mice (Roff et al., 2013; Watanabe et al., 2019; Markowitz et al., 2010).